Vanda Pharmaceuticals Inc
VNDA
View Detailed Chart
4.375USD
-0.035-0.79%
Market hours （ET）Quotes delayed by 15 min
258.54MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.79%
5 Days
+1.27%
1 Month
-18.98%
6 Months
+0.11%
Year to Date
-8.66%
1 Year
-10.53%
View Detailed Chart
TradingKey Stock Score of Vanda Pharmaceuticals Inc
Currency: USD Updated: 2025-11-06Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vanda Pharmaceuticals Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
11.750
Target Price
+164.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Vanda Pharmaceuticals Inc Highlights
StrengthsRisks
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -3.08, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 46.47M shares, decreasing 17.64% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 5.17K shares of this stock.
Vanda Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Vanda Pharmaceuticals Inc Info
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Ticker SymbolVNDA
CompanyVanda Pharmaceuticals Inc
CEODr. Mihael Hristos Polymeropoulos, M.D.
Websitehttps://www.vandapharma.com/
Related Instruments
-2.07%
-0.07%
+0.02%
+1.33%
-0.18%
-0.89%
+0.29%
+1.39%
-1.59%
-3.48%
-0.06%
+0.16%
-1.63%
+0.34%
-1.09%
+0.74%
0.00%
+0.72%
-0.43%
-0.07%Popular Symbols
